Treatment of isoniazid-resistant pulmonary tuberculosis

BMC Infectious Diseases

Volumn 8, Issue , 2008, Pages

  Kim, Yee Hyung ^a   Suh, Gee Young ^a   Chung, Man Pyo ^a   Kim, Hojoong ^a   Kwon, O Jung ^a   Lim, Seong Yong ^a   Lim, Si Young ^a   Koh, Won Jung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; LUNG INJURY; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; MEDICAL AUDIT; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; RETROSPECTIVE STUDY; TUBERCULOSIS;

ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MALE; MEDICAL AUDIT; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 39549100357     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-8-6     Document Type: Article

References (21)

1. Pablos-Mendez A Raviglione MC Laszlo A Binkin N Rieder HL Bustreo F Cohn DL Lambregts-van Weezenbeek CS Kim SJ Chaulet P Nunn P Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance N Engl J Med 1998, 338:1641-1649 10.1056/NEJM199806043382301 9614254
2. Dye C Scheele S Dolin P Pathania V Raviglione MC Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project JAMA 1999, 282:677-686 10.1001/jama.282.7.677 10517722
3. Espinal MA Laszlo A Simonsen L Boulahbal F Kim SJ Reniero A Hoffner S Rieder HL Binkin N Dye C Williams R Raviglione MC Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance N Engl J Med 2001, 344:1294-1303 10.1056/NEJM200104263441706 11320389
4. Mitchison DA Nunn AJ Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis Am Rev Respir Dis 1986, 133:423-430 2420242
5. American Thoracic Society, Centers for Disease Control and Prevention Treatment of tuberculosis and tuberculosis infection in adults and children Am J Respir Crit Care Med 1994, 149:1359-1374 8173779
6. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America Treatment of tuberculosis Am J Respir Crit Care Med 2003, 167:603-662 10.1164/rccm.167.4.603 12588714
7. Joint Tuberculosis Committee of the British Thoracic Society Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998 Thorax 1998, 53:536-548 9797751
8. Koh WJ Kwon OJ Park YK Lew WJ Bai GH Development of multidrug resistance during treatment of isoniazid-resistant tuberculosis Eur Respir J 2005, 26:557 10.1183/09031936.05.00045605 16135740
9. Bai GH Park YK Choi YW Bai JI Kim HJ Chang CL Lee JK Kim SJ Trend of anti-tuberculosis drug resistance in Korea, 1994-2004 Int J Tuberc Lung Dis 2007, 11:571-576 17439684
10. Kim SJ Drug-susceptibility testing in tuberculosis: Methods and reliability of results Eur Respir J 2005, 25:564-569 10.1183/ 09031936.05.00111304 15738303
11. Task Force of the European Respiratory Society, the World Health Organisation and the International Union against Tuberculosis and Lung Disease Europe Region Tuberculosis management in Europe Eur Respir J 1999, 14:978-992 10.1034/j.1399-3003.1999.14d43.x 10573254
12. World Health Organization Treatment of tuberculosis: Guidelines for national programmes, WHO/CDS/TB/2003. 313 Geneva, Switzerland: WHO 3 2003:313
13. Seung KJ Bai GH Kim SJ Lew WJ Park SK Kim JY The treatment of tuberculosis in South Korea Int J Tuberc Lung Dis 2003, 7:912-919 14552560
14. Lee BH Koh WJ Choi MS Suh GY Chung MP Kim H Kwon OJ Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy Chest 2005, 127:1304-1311 10.1378/chest.127.4.1304 15821209
15. Kwon YS Koh WJ Suh GY Chung MP Kim H Kwon OJ Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy Chest 2007, 131:803-808 10.1378/chest.06-2042 17356096
16. Espinal MA Kim SJ Suarez PG Kam KM Khomenko AG Migliori GB Baez J Kochi A Dye C Raviglione MC Standard short-course chemotherapy for drug-resistant tuberculosis: Treatment outcomes in 6 countries JAMA 2000, 283:2537-2545 10.1001/jama.283.19.2537 10815117
17. Seung KJ Gelmanova IE Peremitin GG Golubchikova VT Pavlova VE Sirotkina OB Yanova GV Strelis AK The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis Clin Infect Dis 2004, 39:1321-1328 10.1086/425005 15494909
18. Babu Swai O Aluoch JA Githui WA Thiong'o R Edwards EA Darbyshire JH Nunn AJ Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis Tubercle 1988, 69:5-14 10.1016/0041-3879(88)90035-9 3051607
19. Ormerod LP Horsfield N Green RM Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started? J Infect 2001, 42:1-3 10.1053/jinf.2000.0773 11243745
20. Escalante P Graviss EA Griffith DE Musser JM Awe RJ Treatment of isoniazid-resistant tuberculosis in southeastern Texas Chest 2001, 119:1730-1736 10.1378/chest.119.6.1730 11399698
21. World Health Organization Guidelines for the progammatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361 Geneva, Switzerland: WHO 2006